NASDAQ:IONS 22 August 2025

Cathie Wood’s early investment in SpaceX (NASDAQ:SPCX) shows loss ahead of lockup expiration

ARK Invest’s recent SpaceX buy showed an estimated paper loss of $1.09 million in Friday's premarket trade. The figure was about $599,000 at Thursday’s close.

17 July 2026

ETFs·NASDAQ:AMD·NASDAQ:IONS·NASDAQ:SPCX·NASDAQ:TSLA·NYSE:CRCL·Space Industry·Stock Market

Biotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tape

Biotech names Vertex Pharmaceuticals and Ionis Pharmaceuticals slumped after two big setbacks, wiping out about $14.8 billion in market value over the five sessions through Friday. That's going by Friday's share counts and using July 2 and July 10 close, even as a takeover target in the sector almost doubled.

11 July 2026

NASDAQ:IONS·NASDAQ:VRTX·Pharmaceuticals·Stock Market

Ionis (NASDAQ:IONS) shares slump as failed trial triggers $3B selloff

Ionis Pharmaceuticals dropped about $3.2 billion in market cap Thursday after its partner AstraZeneca’s heart drug Wainua missed the primary endpoint in a key late-stage trial. Shares of Ionis traded at $64.83, off 23.2%, as of 2:46 p.m. ET. By then, the SPDR S&P Biotech ETF was up 0.7%, and iShares Nasdaq Biotechnology ETF gained 0.2%.

9 July 2026

NASDAQ:IONS·Pharmaceutical Industry·Stock Market

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

This comprehensive roundup highlights the fast-moving developments in biotech, pharma, and health over the past 48 hours. From life-saving drugs and high-stakes deals to public health challenges, the landscape is evolving daily. As always, readers are advised to consult original sources and official health guidance for more details.

25 August 2025

NASDAQ:BIIB·NASDAQ:CMRX·NASDAQ:IONS·NASDAQ:JAZZ·NASDAQ:MITO·NASDAQ:PTCT·Stock Market

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.

23 August 2025

ASX:CSL·Health News·NASDAQ:IONS·NASDAQ:KALV·NASDAQ:SRRK·NYSE:ABBV·NYSE:LLY·Pharmaceuticals

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Sources: Scientific press releases, company announcements, major news outlets, and health agency briefs were used to compile this report reuters.com reuters.com ts2.tech interiusbio.com. Each item includes a citation link to the original source for further reading. This concludes the comprehensive roundup of biotech, pharma, medical, and health news from August 21–22, 2025.

22 August 2025

NASDAQ:GILD·NASDAQ:IONS·NASDAQ:PRGN·NASDAQ:XOMA·NYSE:JNJ·Pharmaceuticals